Who founded Venus Concept?

Venus Concept was founded by Domenic Serafino in 2009.

Who are Venus Concept's investors?

Venus Concept's investors include APERTURE Venture Partners, Essex Woodlands Healthcare Partners, Longitude Capital, Clarus, HealthQuest Capital.

How much funding has Venus Concept raised?

Venus Concept has disclosed $219.3M raised across 13 of its 14 known rounds.

Where is Venus Concept headquartered?

Venus Concept is headquartered in Toronto, US.

Venus Concept

Toronto, US · Founded 2009 · Delaware corporation · 421 employees on LinkedIn · 5 known investors

Find your way into Venus Concept

Venus develops non-invasive, energy-based medical aesthetic devices for body, face, skin, and hair treatments, integrating robotics, AI, and IoT technologies. It serves medical spas, dermatologists, plastic surgeons, and hair transplant physicians across more than 60 countries.

Biotech Hardware Healthtech Medical Devices

Founders & leadership

Venus Concept was founded in 2009 by Domenic Serafino.

Domenic SerafinoinFounder

Kirk GunhusinChief Revenue Officer (CRO)2025–2026Kirk Gunhus held management positions at Ciba Vision and Medicis, where he sold aesthetic treatments including Restylane and Dysport, before joining Zeltiq as regional director. He is now Executive Officer at Venus Concept, which develops energy-based medical aesthetic devices for dermatology and cosmetic applications.

Ross PortaroinExecutive Vice-President Commercial StrategyRoss Portaro is an executive officer at Venus Concept, a medical device company developing non-invasive energy-based aesthetic devices. He has held senior leadership positions in the medical device and healthcare sectors, with experience in commercial strategy, global expansion, product portfolio management, and organizational restructuring.

Anna GeorgiadisinChief Human Resources Officer

Melissa KanginChief Product OfficerMelissa Kang is an Executive Officer at Venus Concept with over 20 years of experience in medical aesthetics, including roles in marketing, product management, R&D, regulatory affairs, and business development for toxins, dermal fillers, and medical devices. She holds an MBA from Queen's University, a CPA and CMA designation, and a BSc in Chemistry, and has led cross-functional global teams across more than 60 countries.

Michael MandarelloinChief Legal Officer & Chief Operations Officer

Dominic Della PennaExecutive

Rajiv De SilvaChief Executive Officer and Director

James McCollumDirector, President and Chief Executive Officer

William KelleyNamed on SEC filing

Boris VaynberginCTO2013–2020Chief Technology Officer (CTO) at INDIBA

Greg Van StaverenNamed on SEC filing

Investors · 5

APERTURE Venture PartnersBoston · $1M – $5M

Essex Woodlands Healthcare PartnersNew York · $20M – $80M

Longitude CapitalMenlo Park · $10M – $30Mvia Juliet Bakker · board

ClarusreportedCambridge

HealthQuest CapitalreportedRedwood City

Reported raises · per SEC filings

Form D private placements

$219.3M disclosed across 13 of 14 rounds · 2013–2026

▶$1.5MraisedApr 2026 · 2 investors · Other Health Care

Rule 506(b)